Future therapies for eosinophilic gastrointestinal disorders

Robert D. Pesek, Sandeep K. Gupta

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Objective: To review novel therapeutics in development for treatment of eosinophilic gastrointestinal disorders (EGIDs). Data Sources: Clinical trial data (clinicaltrials.gov) and literature search on PubMed. Study Selections: Studies on treatment and clinical trials in EGIDs were included in this review. Results: During the past decade, significant progress has been made in understanding disease mechanisms in EGIDs. As a result, a variety of novel therapeutics have been developed for treatment of these disorders. Several monoclonal antibodies against targets, including interleukin (IL) 4, IL-5, IL-13, integrins, and siglec-8, have shown promise in early trials. Novel formulations of corticosteroids are also in development. Conclusion: The field of EGID research has advanced rapidly, and disease-modifying therapeutics are closer to clinical application.

Original languageEnglish (US)
Pages (from-to)219-226
Number of pages8
JournalAnnals of Allergy, Asthma and Immunology
Issue number3
StatePublished - Mar 2020

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Future therapies for eosinophilic gastrointestinal disorders'. Together they form a unique fingerprint.

Cite this